therapeutic autologous dendritic cells
Merck Advances Middle Dose of ROR1 ADC in Relapsed/Refractory DLBCL After Safety Review
Merck; ROR1; ADC; zilovertamab vedotin; middle dose; 1.75 mg/kg; relapsed DLBCL; refractory DLBCL; WaveLINE-003; safety; adverse events; clinical trial; ASCO 2025
Astellas Secures $1.34B Licensing Deal for CLDN18.2-Targeted ADC with Evopoint Biosciences
Astellas; Evopoint Biosciences; CLDN18.2; antibody-drug conjugate; ADC; licensing deal; oncology; XNW27011
Merck, Daiichi Sankyo Withdraw FDA Application for HER3-Targeting ADC After Survival Endpoint Miss
Merck; Daiichi Sankyo; patritumab deruxtecan; HER3 ADC; FDA application; non-small cell lung cancer; clinical trial; overall survival; application withdrawal
AbbVie Advances Solid Tumor Program with FDA Approval of Emrelis for Lung Cancer
AbbVie; Emrelis; FDA Approval; ADC; solid tumor; lung cancer; non-small cell lung cancer; c-Met overexpression; telisotuzumab vedotin-tllv; accelerated approval
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
OBT, therapeutic autologous dendritic cells, Roche (company), Partnership, Oxford BioTherapeutics, Antibody-Drug Conjugates, biobucks, New
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash
Synaffix Expands ADC Licensing Partnerships with Boehringer Ingelheim and Mitsubishi Tanabe
Synaffix, Boehringer Ingelheim, Mitsubishi Tanabe, ADC technology, oncology, cancer treatment, licensing agreement
Roche’s Chugai Enters $780M Deal with Swiss ADC Specialist Araris Biotech
Roche, Chugai, Araris Biotech, ADC, Antibody-Drug Conjugate, Biotech Deal
GSK Expands Eastern Partnerships with $30M Option on DualityBio’s Preclinical ADC
GSK, DualityBio, ADC, Preclinical, Biotech, Pharmaceutical Partnerships
Gilead Partners with Tubulis for Solid Tumor ADC Development in Deal Worth Up to $465M
Gilead, Tubulis, ADC, Solid Tumor, Biotech, Partnership